Cardiac Pathways searches for new financial strategy as it breaches bank loan conditions
This article was originally published in Clinica
Cardiac Pathways, a pioneer in minimally-invasive integrated mapping and ablation systems for cardiac tachyarrhythmias, has breached the conditions of its bank loans and has hired Morgan Stanley as financial adviser to pursue strategic alternatives for its future. These include finding new capital for the Sunnyvale, California company, or selling it.
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.